220 related articles for article (PubMed ID: 21791135)
1. [Determining cardiovascular risk in patients with rheumatoid arthritis: waiting for trial outcomes is not recommended].
Nurmohamed MT
Ned Tijdschr Geneeskd; 2011; 155(29):A3485. PubMed ID: 21791135
[TBL] [Abstract][Full Text] [Related]
2. [Determining cardiovascular risk in patients with rheumatoid arthritis: waiting for trial outcomes is not recommended].
Nurmohamed MT
Ned Tijdschr Geneeskd; 2011; 155(30-31):A3485. PubMed ID: 22085512
[TBL] [Abstract][Full Text] [Related]
3. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.
Peters MJ; Symmons DP; McCarey D; Dijkmans BA; Nicola P; Kvien TK; McInnes IB; Haentzschel H; Gonzalez-Gay MA; Provan S; Semb A; Sidiropoulos P; Kitas G; Smulders YM; Soubrier M; Szekanecz Z; Sattar N; Nurmohamed MT
Ann Rheum Dis; 2010 Feb; 69(2):325-31. PubMed ID: 19773290
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk in rheumatoid arthritis.
Nurmohamed MT
Autoimmun Rev; 2009 Jul; 8(8):663-7. PubMed ID: 19393192
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications.
Pieringer H; Pichler M
QJM; 2011 Jan; 104(1):13-26. PubMed ID: 21068083
[TBL] [Abstract][Full Text] [Related]
6. Statins in hypertension: are they a new class of antihypertensive agents?
Feldstein CA
Am J Ther; 2010; 17(3):255-62. PubMed ID: 19918164
[TBL] [Abstract][Full Text] [Related]
7. Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis.
Giles JT; Post W; Blumenthal RS; Bathon JM
Nat Clin Pract Rheumatol; 2006 Jun; 2(6):320-9. PubMed ID: 16932711
[TBL] [Abstract][Full Text] [Related]
8. [Cardiovascular diseases and rheumatoid arthritis].
Morović-Vergles J
Reumatizam; 2010; 57(2):11-5. PubMed ID: 21874999
[TBL] [Abstract][Full Text] [Related]
9. Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study.
Chapman RH; Petrilla AA; Berman L; Benner JS; Tang SS
Am J Cardiovasc Drugs; 2009; 9(5):299-308. PubMed ID: 19791839
[TBL] [Abstract][Full Text] [Related]
10. [Determining cardiovascular risk in patients with rheumatoid arthritis: prove the efficacy of interventions first].
Thomas S
Ned Tijdschr Geneeskd; 2011; 155(29):A3563. PubMed ID: 21791140
[TBL] [Abstract][Full Text] [Related]
11. [Cardiovascular comorbidity in rheumatic disease. Does sex play a role?].
Kung M; Störk S; Angermann CE
Herz; 2005 Sep; 30(6):512-21. PubMed ID: 16170682
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project.
van den Oever IAM; Heslinga M; Griep EN; Griep-Wentink HRM; Schotsman R; Cambach W; Dijkmans BAC; Smulders YM; Lems WF; Boers M; Voskuyl AE; Peters MJL; van Schaardenburg D; Nurmohamed MT
Rheumatology (Oxford); 2017 Sep; 56(9):1472-1478. PubMed ID: 28199724
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for cardiovascular disease in rheumatoid arthritis.
Gabriel SE; Crowson CS
Curr Opin Rheumatol; 2012 Mar; 24(2):171-6. PubMed ID: 22249350
[TBL] [Abstract][Full Text] [Related]
15. The utility of cardiovascular drugs in the treatment of cerebrovascular disease.
Bösel J; Amiri H
Curr Opin Investig Drugs; 2010 Sep; 11(9):1015-24. PubMed ID: 20730696
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular disease in rheumatoid arthritis: disease and treatment interactions and their implications on treatment decisions.
Sanders S; Geraci SA
J Miss State Med Assoc; 2010 Mar; 51(3):75-80. PubMed ID: 20827876
[TBL] [Abstract][Full Text] [Related]
17. Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis.
Carroll L; Frazer IH; Turner M; Marwick TH; Thomas R
Arthritis Res Ther; 2007; 9(2):R39. PubMed ID: 17425804
[TBL] [Abstract][Full Text] [Related]
18. [Prevention of cardiovascular diseases in rheumatoid arthritis].
Novikova DS; Popkova TV; Nasonov EL
Ter Arkh; 2009; 81(5):88-96. PubMed ID: 19537595
[TBL] [Abstract][Full Text] [Related]
19. Cardiometabolic risk-factor management.
Ker J
Cardiovasc J Afr; 2008; 19(4):222-4. PubMed ID: 18776972
[No Abstract] [Full Text] [Related]
20. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
Solomon DH; Avorn J; Katz JN; Weinblatt ME; Setoguchi S; Levin R; Schneeweiss S
Arthritis Rheum; 2006 Dec; 54(12):3790-8. PubMed ID: 17136752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
